- Home
- ASIX vs MNPR Comparison
ASIX vs MNPR Comparison
Compare ASIX & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASIX
- MNPR
- Stock Information
- Founded
- ASIX 2016
- MNPR 2014
- Country
- ASIX United States
- MNPR United States
- Employees
- ASIX N/A
- MNPR N/A
- Industry
- ASIX Major Chemicals
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- ASIX Industrials
- MNPR Health Care
- Exchange
- ASIX Nasdaq
- MNPR Nasdaq
- Market Cap
- ASIX 526.1M
- MNPR 531.6M
- IPO Year
- ASIX N/A
- MNPR 2019
- Fundamental
- Price
- ASIX $14.98
- MNPR $80.00
- Analyst Decision
- ASIX Buy
- MNPR Strong Buy
- Analyst Count
- ASIX 1
- MNPR 12
- Target Price
- ASIX $32.00
- MNPR $96.64
- AVG Volume (30 Days)
- ASIX 272.8K
- MNPR 100.1K
- Earning Date
- ASIX 11-07-2025
- MNPR 11-10-2025
- Dividend Yield
- ASIX 3.50%
- MNPR N/A
- EPS Growth
- ASIX 829.30
- MNPR N/A
- EPS
- ASIX 2.84
- MNPR N/A
- Revenue
- ASIX $1,515,062,000.00
- MNPR N/A
- Revenue This Year
- ASIX $4.71
- MNPR N/A
- Revenue Next Year
- ASIX $4.59
- MNPR N/A
- P/E Ratio
- ASIX $6.43
- MNPR N/A
- Revenue Growth
- ASIX 1.31
- MNPR N/A
- 52 Week Low
- ASIX $17.97
- MNPR $14.88
- 52 Week High
- ASIX $33.00
- MNPR $105.00
- Technical
- Relative Strength Index (RSI)
- ASIX 18.81
- MNPR 46.97
- Support Level
- ASIX $18.20
- MNPR $77.00
- Resistance Level
- ASIX $19.01
- MNPR $86.14
- Average True Range (ATR)
- ASIX 0.76
- MNPR 5.59
- MACD
- ASIX -0.32
- MNPR -1.34
- Stochastic Oscillator
- ASIX 3.17
- MNPR 40.01
About ASIX AdvanSix Inc.
AdvanSix Inc. is a diversified chemistry company playing a critical role in globally supply chains, innovating and delivering essential products for customers in a wide variety of end markets and applications that touch people's lives, such as building and construction, fertilizers, agrochemicals, plastics, solvents, packaging, paints, coatings, adhesives and electronics. The company key products includes: Nylon, Caprolactam, Plant Nutrients, and Chemical Intermediates The majority of sales is from Plant Nutrients products.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.